

Resource Summary Report

Generated by [T1D](#) on Aug 1, 2026

IUPHAR/BPS Guide to Pharmacology

RRID:SCR_013077

Type: Tool

Proper Citation

IUPHAR/BPS Guide to Pharmacology (RRID:SCR_013077)

Resource Information

URL: <http://www.guidetopharmacology.org>

Proper Citation: IUPHAR/BPS Guide to Pharmacology (RRID:SCR_013077)

Description: Portal and searchable database of pharmacological information. Information is presented at two levels, the initial view or landing pages for each target family provide expert-curated overviews of the key properties and the available selective ligands and tool compounds. For selected targets, more detailed introductory chapters for each family are available along with curated information on the pharmacological, physiological, structural, genetic and pathophysiological properties of each target.

Abbreviations: IUPHAR Database, IUPHAR-DB, IUPHAR GPCR, IUPHAR RECEPTOR

Synonyms: International Union of Pharmacology Database, International Union of Basic and Clinical Pharmacology Database

Resource Type: data or information resource, portal, narrative resource, database, standard specification

Defining Citation: [PMID:21087994](#)

Keywords: pharmacology, drug discovery, portal, guide, physiology, molecular structure, bio.tools, FASEB list

Funding: Wellcome Trust

Resource Name: IUPHAR/BPS Guide to Pharmacology

Resource ID: SCR_013077

Alternate IDs: nif-0000-03056, biotools:iuphar-db, r3d100013308

Alternate URLs: <https://bio.tools/iuphar-db>, <https://doi.org/10.17616/R31NJMRG>

Old URLs: <http://www.iuphar-db.org>

Record Creation Time: 20220129T080314+0000

Record Last Update: 20260801T042713+0000

Ratings and Alerts

No rating or validation information has been found for IUPHAR/BPS Guide to Pharmacology.

No alerts have been found for IUPHAR/BPS Guide to Pharmacology.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2259 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Suarez-Kurtz G, et al. (2026) Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels. British journal of clinical pharmacology, 92(1), 109.

Hsu CC, et al. (2026) Effectiveness and safety of combining thiazides with loop diuretics vs. loop diuretics monotherapy in patients with acute decompensated heart failure: A retrospective cohort study. British journal of clinical pharmacology, 92(1), 220.

de Groot ADE, et al. (2026) Ileal bile acid transporter inhibitors in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis: A systematic review into dose-response. British journal of clinical pharmacology, 92(1), 119.

Thomas O, et al. (2026) GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study. British journal of clinical pharmacology, 92(1), 312.

Whiteside GT, et al. (2026) Efficacy and safety of a selective partial agonist for nociception/orphanin-FQ peptide (NOP) receptors in patients with insomnia disorder. British journal of clinical pharmacology, 92(1), 172.

Thomasius F, et al. (2026) Adjuvant pharmacological strategies for the musculoskeletal system during long-term space missions. British journal of clinical pharmacology, 92(1), 11.

Peruzzi E, et al. (2025) Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? British journal of clinical pharmacology, 91(2), 270.

Andrighetti NB, et al. (2025) Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea. *British journal of clinical pharmacology*, 91(12), 3412.

D'Agate S, et al. (2025) Optimizing β -lactam-containing antibiotic combination therapy for the treatment of Buruli ulcer. *British journal of clinical pharmacology*, 91(1), 179.

Yeung SA, et al. (2025) The pharmacokinetics of brensocatic in participants with renal impairment following a single oral administration. *British journal of clinical pharmacology*, 91(4), 1191.

Agergaard K, et al. (2025) Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney-transplanted patients. *British journal of clinical pharmacology*, 91(3), 761.

Giraud EL, et al. (2025) Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer. *British journal of clinical pharmacology*, 91(2), 297.

Soeria-Atmadja S, et al. (2025) Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study. *British journal of clinical pharmacology*, 91(2), 464.

Wu AS, et al. (2025) Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency. *British journal of clinical pharmacology*, 91(5), 1511.

Kumagai Y, et al. (2025) Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies. *British journal of clinical pharmacology*, 91(8), 2340.

Pottegård A, et al. (2025) Trends in gabapentinoid prescribing: A nationwide Danish drug utilization study. *British journal of clinical pharmacology*, 91(9), 2515.

Johnson M, et al. (2025) Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer. *Pharmacology research & perspectives*, 13(3), e70098.

Kinzi J, et al. (2025) Insights Into Atorvastatin Pharmacokinetics in Rats Reveal Regulation of CYP3A1 by Humanization of SLCO2B1. *Pharmacology research & perspectives*, 13(4), e70133.

Giacon M, et al. (2025) Credibility of genetic predictors for antiepileptic drug resistance: A systematic Bayesian reappraisal of published meta-analyses. *British journal of clinical pharmacology*, 91(10), 2782.

Ghasemi M, et al. (2025) Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia-inducible factor-2 α inhibitor, in healthy participants. *British journal of clinical pharmacology*, 91(12), 3366.